References
1. Hsu J, Avila PC, Kern RC, Hayes MG, Schleimer RP, Pinto JM. Genetics
of chronic rhinosinusitis: state of the field and directions forward.J Allergy Clin Immunol. 2013;131(4):977-993, 993 e971-975.
2. Stevens WW, Lee RJ, Schleimer RP, Cohen NA. Chronic rhinosinusitis
pathogenesis. J Allergy Clin Immunol. 2015;136(6):1442-1453.
3. Gudis D, Zhao KQ, Cohen NA. Acquired cilia dysfunction in chronic
rhinosinusitis. Am J Rhinol Allergy. 2012;26(1):1-6.
4. Stammberger H, Posawetz W. Functional endoscopic sinus surgery.
Concept, indications and results of the Messerklinger technique.Eur Arch Otorhinolaryngol. 1990;247(2):63-76.
5. Song WJ, Lee JH, Won HK, Bachert C. Chronic Rhinosinusitis with Nasal
Polyps in Older Adults: Clinical Presentation, Pathophysiology, and
Comorbidity. Curr Allergy Asthma Rep. 2019;19(10):46.
6. Chang EH, Stern DA, Willis AL, Guerra S, Wright AL, Martinez FD.
Early life risk factors for chronic sinusitis: A longitudinal birth
cohort study. J Allergy Clin Immunol. 2018;141(4):1291-1297
e1292.
7. DelGaudio JM, Loftus PA, Hamizan AW, Harvey RJ, Wise SK. Central
compartment atopic disease. Am J Rhinol Allergy.2017;31(4):228-234.
8. Bacciu A, Buzio C, Giordano D, et al. Nasal polyposis in
Churg-Strauss syndrome. Laryngoscope. 2008;118(2):325-329.
9. Ocampo CJ, Peters AT. Antibody deficiency in chronic rhinosinusitis:
epidemiology and burden of illness. Am J Rhinol Allergy.2013;27(1):34-38.
10. Ponikau JU, Sherris DA, Kern EB, et al. The diagnosis and incidence
of allergic fungal sinusitis. Mayo Clin Proc. 1999;74(9):877-884.
11. Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P.
Total and specific IgE in nasal polyps is related to local eosinophilic
inflammation. J Allergy Clin Immunol. 2001;107(4):607-614.
12. Perloff JR, Palmer JN. Evidence of bacterial biofilms on frontal
recess stents in patients with chronic rhinosinusitis. Am J
Rhinol. 2004;18(6):377-380.
13. Kern RC, Conley DB, Walsh W, et al. Perspectives on the etiology of
chronic rhinosinusitis: an immune barrier hypothesis. Am J
Rhinol. 2008;22(6):549-559.
14. Abreu NA, Nagalingam NA, Song Y, et al. Sinus microbiome diversity
depletion and Corynebacterium tuberculostearicum enrichment mediates
rhinosinusitis. Sci Transl Med. 2012;4(151):151ra124.
15. Tan BK, Lu G, Kwasny MJ, et al. Effect of symptom-based risk
stratification on the costs of managing patients with chronic
rhinosinusitis symptoms. Int Forum Allergy Rhinol.2013;3(11):933-940.
16. Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of
chronic rhinosinusitis: a PRACTALL document of the European Academy of
Allergy and Clinical Immunology and the American Academy of Allergy,
Asthma & Immunology. J Allergy Clin Immunol.2013;131(6):1479-1490.
17. Harlin SL, Ansel DG, Lane SR, Myers J, Kephart GM, Gleich GJ. A
clinical and pathologic study of chronic sinusitis: the role of the
eosinophil. J Allergy Clin Immunol. 1988;81(5 Pt 1):867-875.
18. Stoop AE, van der Heijden HA, Biewenga J, van der Baan S.
Eosinophils in nasal polyps and nasal mucosa: an immunohistochemical
study. J Allergy Clin Immunol. 1993;91(2):616-622.
19. Jankowski R, Bene MC, Moneret-Vautrin AD, et al. Immunohistological
characteristics of nasal polyps. A comparison with healthy mucosa and
chronic sinusitis. Rhinol Suppl. 1989;8:51-58.
20. Mygind N. Nasal polyposis. J Allergy Clin Immunol. 1990;86(6
Pt 1):827-829.
21. Fokkens WJ, Holm AF, Rijntjes E, Mulder PG, Vroom TM.
Characterization and quantification of cellular infiltrates in nasal
mucosa of patients with grass pollen allergy, non-allergic patients with
nasal polyps and controls. Int Arch Allergy Appl Immunol.1990;93(1):66-72.
22. Drake-Lee A, Price J. Mast cell ultrastructure in the inferior
turbinate and stroma of nasal polyps. J Laryngol Otol.1997;111(4):340-345.
23. Polzehl D, Moeller P, Riechelmann H, Perner S. Distinct features of
chronic rhinosinusitis with and without nasal polyps. Allergy.2006;61(11):1275-1279.
24. Huvenne W, van Bruaene N, Zhang N, et al. Chronic rhinosinusitis
with and without nasal polyps: what is the difference? Curr
Allergy Asthma Rep. 2009;9(3):213-220.
25. Sobol SE, Christodoulopoulos P, Manoukian JJ, et al. Cytokine
profile of chronic sinusitis in patients with cystic fibrosis.Arch Otolaryngol Head Neck Surg. 2002;128(11):1295-1298.
26. Soler ZM, Sauer D, Mace J, Smith TL. Impact of mucosal eosinophilia
and nasal polyposis on quality-of-life outcomes after sinus surgery.Otolaryngol Head Neck Surg. 2010;142(1):64-71.
27. Stierna P, Carlsoo B. Histopathological observations in chronic
maxillary sinusitis. Acta Otolaryngol. 1990;110(5-6):450-458.
28. Berger G, Kattan A, Bernheim J, Ophir D. Polypoid mucosa with
eosinophilia and glandular hyperplasia in chronic sinusitis: a
histopathological and immunohistochemical study. Laryngoscope.2002;112(4):738-745.
29. Malekzadeh S, McGuire JF. The new histologic classification of
chronic rhinosinusitis. Curr Allergy Asthma Rep.2003;3(3):221-226.
30. Kuhar HN, Tajudeen BA, Heilingoetter A, et al. Distinct
histopathologic features of radiation-induced chronic sinusitis.Int Forum Allergy Rhinol. 2017;7(10):990-998.
31. Brescia G, Alessandrini L, Marioni G. Structured histopathology for
endotyping and planning rational treatment in chronic rhinosinusitis.Am J Otolaryngol. 2021;42(1):102795.
32. Takabayashi T, Kato A, Peters AT, et al. Excessive fibrin deposition
in nasal polyps caused by fibrinolytic impairment through reduction of
tissue plasminogen activator expression. Am J Respir Crit Care
Med. 2013;187(1):49-57.
33. Takabayashi T, Kato A, Peters AT, et al. Increased expression of
factor XIII-A in patients with chronic rhinosinusitis with nasal polyps.J Allergy Clin Immunol. 2013.
34. Chen CL, Yao Y, Pan L, et al. Common fibrin deposition and tissue
plasminogen activator downregulation in nasal polyps with distinct
inflammatory endotypes. J Allergy Clin Immunol.2020;146(3):677-681.
35. Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is
upregulated in human nasal polyp tissue. J Allergy Clin Immunol.1997;99(6 Pt 1):837-842.
36. Bachert C, Wagenmann M, Rudack C, et al. The role of cytokines in
infectious sinusitis and nasal polyposis. Allergy.1998;53(1):2-13.
37. Takeuchi K, Yuta A, Sakakura Y. Interleukin-8 gene expression in
chronic sinusitis. Am J Otolaryngol. 1995;16(2):98-102.
38. Suzuki H, Takahashi Y, Wataya H, et al. Mechanism of neutrophil
recruitment induced by IL-8 in chronic sinusitis. J Allergy Clin
Immunol. 1996;98(3):659-670.
39. Riechelmann H, Deutschle T, Rozsasi A, Keck T, Polzehl D, Burner H.
Nasal biomarker profiles in acute and chronic rhinosinusitis. Clin
Exp Allergy. 2005;35(9):1186-1191.
40. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic
sinus diseases by measurement of inflammatory mediators. Allergy.2006;61(11):1280-1289.
41. Cao PP, Li HB, Wang BF, et al. Distinct immunopathologic
characteristics of various types of chronic rhinosinusitis in adult
Chinese. J Allergy Clin Immunol. 2009;124(3):478-484, 484
e471-472.
42. Zhang N, Van Zele T, Perez-Novo C, et al. Different types of
T-effector cells orchestrate mucosal inflammation in chronic sinus
disease. J Allergy Clin Immunol. 2008;122(5):961-968.
43. Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes
of chronic rhinosinusitis based on cluster analysis of biomarkers.J Allergy Clin Immunol. 2016;137(5):1449-1456 e1444.
44. Bachert C, Akdis CA. Phenotypes and Emerging Endotypes of Chronic
Rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):621-628.
45. Kato A. Immunopathology of chronic rhinosinusitis. Allergol
Int. 2015;64(2):121-130.
46. Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal
Polyposis. Annu Rev Pathol. 2017;12:331-357.
47. Peterson S, Poposki JA, Nagarkar DR, et al. Increased expression of
CC chemokine ligand 18 in patients with chronic rhinosinusitis with
nasal polyps. J Allergy Clin Immunol. 2012;129(1):119-127
e111-119.
48. Takabayashi T, Kato A, Peters AT, et al. Glandular mast cells with
distinct phenotype are highly elevated in chronic rhinosinusitis with
nasal polyps. J Allergy Clin Immunol. 2012;130(2):410-420 e415.
49. Hulse KE, Norton JE, Suh L, et al. Chronic rhinosinusitis with nasal
polyps is characterized by B-cell inflammation and EBV-induced protein 2
expression. J Allergy Clin Immunol. 2013;131(4):1075-1083, 1083
e1071-1077.
50. Derycke L, Eyerich S, Van Crombruggen K, et al. Mixed T helper cell
signatures in chronic rhinosinusitis with and without polyps. PLoS
One. 2014;9(6):e97581.
51. Mahdavinia M, Carter RG, Ocampo CJ, et al. Basophils are elevated in
nasal polyps of patients with chronic rhinosinusitis without aspirin
sensitivity. J Allergy Clin Immunol. 2014;133(6):1759-1763.
52. Shi LL, Song J, Xiong P, et al. Disease-specific T-helper cell
polarizing function of lesional dendritic cells in different types of
chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care
Med. 2014;190(6):628-638.
53. Poposki JA, Peterson S, Welch K, et al. Elevated presence of myeloid
dendritic cells in nasal polyps of patients with chronic rhinosinusitis.Clin Exp Allergy. 2015;45(2):384-393.
54. Poposki JA, Klingler AI, Tan BK, et al. Group 2 innate lymphoid
cells are elevated and activated in chronic rhinosinusitis with nasal
polyps. Immun Inflamm Dis. 2017;5(3):233-243.
55. Klingler AI, Stevens WW, Tan BK, et al. Mechanisms and biomarkers of
inflammatory endotypes in chronic rhinosinusitis without nasal polyps.J Allergy Clin Immunol. 2020.
56. Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in
patients with chronic rhinosinusitis: A multicenter study in Europe,
Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344-1353.
57. Tan BK, Klingler AI, Poposki JA, et al. Heterogeneous inflammatory
patterns in chronic rhinosinusitis without nasal polyps in Chicago,
Illinois. J Allergy Clin Immunol. 2017;139(2):699-703 e697.
58. Stevens WW, Peters AT, Tan BK, et al. Associations Between
Inflammatory Endotypes and Clinical Presentations in Chronic
Rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812-2820
e2813.
59. Baba S, Kondo K, Toma-Hirano M, et al. Local increase in IgE and
class switch recombination to IgE in nasal polyps in chronic
rhinosinusitis. Clin Exp Allergy. 2014;44(5):701-712.
60. Plager DA, Kahl JC, Asmann YW, et al. Gene transcription changes in
asthmatic chronic rhinosinusitis with nasal polyps and comparison to
those in atopic dermatitis. PLoS One. 2010;5(7):e11450.
61. Tyler MA, Russell CB, Smith DE, et al. Large-scale gene expression
profiling reveals distinct type 2 inflammatory patterns in chronic
rhinosinusitis subtypes. J Allergy Clin Immunol.2017;139(3):1061-1064 e1064.
62. Wang W, Gao Z, Wang H, et al. Transcriptome Analysis Reveals
Distinct Gene Expression Profiles in Eosinophilic and Noneosinophilic
Chronic Rhinosinusitis with Nasal Polyps. Sci Rep. 2016;6:26604.
63. Okada N, Nakayama T, Asaka D, et al. Distinct gene expression
profiles and regulation networks of nasal polyps in eosinophilic and
non-eosinophilic chronic rhinosinusitis. Int Forum Allergy
Rhinol. 2018;8(5):592-604.
64. Ryu G, Mo JH, Shin HW. Epithelial-to-mesenchymal transition in
neutrophilic chronic rhinosinusitis. Curr Opin Allergy Clin
Immunol. 2021;21(1):30-37.
65. Seshadri S, Rosati M, Lin DC, et al. Regional differences in the
expression of innate host defense molecules in sinonasal mucosa. J
Allergy Clin Immunol. 2013;132(5):1227-1230 e1225.
66. Wen W, Liu W, Zhang L, et al. Increased neutrophilia in nasal polyps
reduces the response to oral corticosteroid therapy. J Allergy
Clin Immunol. 2012;129(6):1522-1528 e1525.
67. Katotomichelakis M, Tantilipikorn P, Holtappels G, et al.
Inflammatory patterns in upper airway disease in the same geographical
area may change over time. Am J Rhinol Allergy.2013;27(5):354-360.
68. Kim SJ, Lee KH, Kim SW, Cho JS, Park YK, Shin SY. Changes in
histological features of nasal polyps in a Korean population over a
17-year period. Otolaryngol Head Neck Surg. 2013;149(3):431-437.
69. Delemarre T, Holtappels G, De Ruyck N, et al. A substantial
neutrophilic inflammation as regular part of severe type 2 chronic
rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020.
70. Delemarre T, Holtappels G, De Ruyck N, et al. Type 2 inflammation in
chronic rhinosinusitis without nasal polyps: Another relevant endotype.J Allergy Clin Immunol. 2020;146(2):337-343 e336.
71. Van Zele T, Gevaert P, Holtappels G, van Cauwenberge P, Bachert C.
Local immunoglobulin production in nasal polyposis is modulated by
superantigens. Clin Exp Allergy. 2007;37(12):1840-1847.
72. Buchheit KM, Dwyer DF, Ordovas-Montanes J, et al. IL-5Ralpha marks
nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated
respiratory disease. J Allergy Clin Immunol.2020;145(6):1574-1584.
73. Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin
activity is increased in nasal polyps of patients with chronic
rhinosinusitis. J Allergy Clin Immunol. 2013;132(3):593-600 e512.
74. Liu T, Li TL, Zhao F, et al. Role of thymic stromal lymphopoietin in
the pathogenesis of nasal polyposis. Am J Med Sci.2011;341(1):40-47.
75. Boita M, Garzaro M, Raimondo L, et al. Eosinophilic inflammation of
chronic rhinosinusitis with nasal polyps is related to OX40 ligand
expression. Innate Immun. 2015;21(2):167-174.
76. Ogasawara N, Klingler AI, Tan BK, et al. Epithelial activators of
type 2 inflammation: Elevation of thymic stromal lymphopoietin, but not
IL-25 or IL-33, in chronic rhinosinusitis with nasal polyps in Chicago,
Illinois. Allergy. 2018;73(11):2251-2254.
77. Stevens WW, Ocampo CJ, Berdnikovs S, et al. Cytokines in Chronic
Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory
Disease. Am J Respir Crit Care Med. 2015;192(6):682-694.
78. Takabayashi T, Schleimer RP. Formation of nasal polyps: The roles of
innate type 2 inflammation and deposition of fibrin. J Allergy
Clin Immunol. 2020;145(3):740-750.
79. Feldman S, Kasjanski R, Poposki J, et al. Chronic airway
inflammation provides a unique environment for B cell activation and
antibody production. Clin Exp Allergy. 2017;47(4):457-466.
80. Van Bruaene N, Perez-Novo CA, Basinski TM, et al. T-cell regulation
in chronic paranasal sinus disease. J Allergy Clin Immunol.2008;121(6):1435-1441, 1441 e1431-1433.
81. Pinu FR, Beale DJ, Paten AM, et al. Systems Biology and Multi-Omics
Integration: Viewpoints from the Metabolomics Research Community.Metabolites. 2019;9(4).
82. Veenstra TD. Systems Biology: Current Progress and Future Outlook.Proteomics. 2020:e2000235.
83. Michalik M, Samet A, Dmowska-Koroblewska A, et al. An Overview of
the Application of Systems Biology in an Understanding of Chronic
Rhinosinusitis (CRS) Development. J Pers Med. 2020;10(4).
84. Kao SS, Bassiouni A, Ramezanpour M, et al. Scoping review of chronic
rhinosinusitis proteomics. Rhinology. 2020;58(5):418-429.
85. Kao SS, Bassiouni A, Ramezanpour M, et al. Proteomic analysis of
nasal mucus samples of healthy patients and patients with chronic
rhinosinusitis. J Allergy Clin Immunol. 2021;147(1):168-178.
86. Fazlollahi F, Kongmanas K, Tanphaichitr N, et al. Lipidomic
profiling of sinus mucosa from patients with chronic rhinosinusitis.Clin Transl Sci. 2015;8(2):107-115.
87. Miyata J, Fukunaga K, Kawashima Y, et al. Dysregulated fatty acid
metabolism in nasal polyp-derived eosinophils from patients with chronic
rhinosinusitis. Allergy. 2019;74(6):1113-1124.
88. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of
aspirin-exacerbated respiratory disease among asthmatic patients: A
meta-analysis of the literature. J Allergy Clin Immunol.2015;135(3):676-681 e671.
89. Stevens WW, Peters AT, Hirsch AG, et al. Clinical Characteristics of
Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and
Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol
Pract. 2017;5(4):1061-1070 e1063.
90. White AA, Stevenson DD. Aspirin-Exacerbated Respiratory Disease.N Engl J Med. 2018;379(11):1060-1070.
91. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of
NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.Allergy. 2019;74(1):28-39.
92. Stevens WW, Jerschow E, Baptist AP, et al. The role of aspirin
desensitization followed by oral aspirin therapy in managing patients
with aspirin-exacerbated respiratory disease: A Work Group Report from
the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the
American Academy of Allergy, Asthma & Immunology. J Allergy Clin
Immunol. 2020.
93. Scott WC, Cahill KN, Milne GL, et al. Inflammatory heterogeneity in
aspirin-exacerbated respiratory disease. J Allergy Clin Immunol.2020.
94. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of
dupilumab in patients with severe chronic rhinosinusitis with nasal
polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two
multicentre, randomised, double-blind, placebo-controlled,
parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650.
95. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of
omalizumab in nasal polyposis: 2 randomized phase 3 trials. J
Allergy Clin Immunol. 2020;146(3):595-605.
96. Laidlaw TM, Mullol J, Fan C, et al. Dupilumab improves nasal polyp
burden and asthma control in patients with CRSwNP and AERD. J
Allergy Clin Immunol Pract. 2019;7(7):2462-2465 e2461.
97. Jakiela B, Soja J, Sladek K, et al. Heterogeneity of lower airway
inflammation in patients with NSAID-exacerbated respiratory disease.J Allergy Clin Immunol. 2020.
98. Laidlaw TM, Boyce JA. Aspirin-Exacerbated Respiratory Disease–New
Prime Suspects. N Engl J Med. 2016;374(5):484-488.
99. Stevens WW, Staudacher AG, Hulse KE, et al. Activation of the
15-lipoxygenase pathway in aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2021;147(2):600-612.
100. Kristjansson RP, Benonisdottir S, Davidsson OB, et al. A
loss-of-function variant in ALOX15 protects against nasal polyps and
chronic rhinosinusitis. Nat Genet. 2019;51(2):267-276.
101. Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D(2): a
dominant mediator of aspirin-exacerbated respiratory disease. J
Allergy Clin Immunol. 2015;135(1):245-252.
102. Wang M, Bu X, Luan G, et al. Distinct type 2-high inflammation
associated molecular signatures of chronic rhinosinusitis with nasal
polyps with comorbid asthma. Clin Transl Allergy. 2020;10:26.
103. Szucs E, Ravandi S, Goossens A, Beel M, Clement PA. Eosinophilia in
the ethmoid mucosa and its relationship to the severity of inflammation
in chronic rhinosinusitis. Am J Rhinol. 2002;16(3):131-134.
104. Kountakis SE, Arango P, Bradley D, Wade ZK, Borish L. Molecular and
cellular staging for the severity of chronic rhinosinusitis.Laryngoscope. 2004;114(11):1895-1905.
105. Morse JC, Li P, Ely KA, et al. Chronic rhinosinusitis in elderly
patients is associated with an exaggerated neutrophilic proinflammatory
response to pathogenic bacteria. J Allergy Clin Immunol.2019;143(3):990-1002 e1006.
106. Van Zele T, Gevaert P, Watelet JB, et al. Staphylococcus aureus
colonization and IgE antibody formation to enterotoxins is increased in
nasal polyposis. J Allergy Clin Immunol. 2004;114(4):981-983.
107. Tripathi A, Kern R, Conley DB, et al. Staphylococcal exotoxins and
nasal polyposis: analysis of systemic and local responses. Am J
Rhinol. 2005;19(4):327-333.
108. Bachert C, Zhang N, Holtappels G, et al. Presence of IL-5 protein
and IgE antibodies to staphylococcal enterotoxins in nasal polyps is
associated with comorbid asthma. J Allergy Clin Immunol.2010;126(5):962-968, 968 e961-966.
109. Jonstam K, Westman M, Holtappels G, Holweg CTJ, Bachert C. Serum
periostin, IgE, and SE-IgE can be used as biomarkers to identify
moderate to severe chronic rhinosinusitis with nasal polyps. J
Allergy Clin Immunol. 2017;140(6):1705-1708 e1703.
110. Soler ZM, Oyer SL, Kern RC, et al. Antimicrobials and chronic
rhinosinusitis with or without polyposis in adults: an evidenced-based
review with recommendations. Int Forum Allergy Rhinol.2013;3(1):31-47.
111. Smith SS, Evans CT, Tan BK, Chandra RK, Smith SB, Kern RC. National
burden of antibiotic use for adult rhinosinusitis. J Allergy Clin
Immunol. 2013;132(5):1230-1232.
112. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on
Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl
S29):1-464.
113. Orlandi RR, Kingdom TT, Smith TL, et al. International consensus
statement on allergy and rhinology: rhinosinusitis 2021. Int Forum
Allergy Rhinol. 2021;11(3):213-739.
114. Gunel C, Bleier BS, Meteoglu I. Antibiotics in eosinophilic chronic
rhinosinusitis: Rethinking maximal antimicrobial medical therapy.Laryngoscope. 2017;127(4):794-796.
115. Bachert C, Gevaert P, Zhang N, van Zele T, Perez-Novo C. Role of
staphylococcal superantigens in airway disease. Chem Immunol
Allergy. 2007;93:214-236.
116. Lan F, Zhang N, Holtappels G, et al. Staphylococcus aureus Induces
a Mucosal Type 2 Immune Response via Epithelial Cell-derived Cytokines.Am J Respir Crit Care Med. 2018;198(4):452-463.
117. Bachert C, Holtappels G, Merabishvili M, et al. Staphylococcus
aureus controls interleukin-5 release in upper airway inflammation.J Proteomics. 2018;180:53-60.
118. Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of
long-term low-dose macrolide administration on neutrophil recruitment
and IL-8 in the nasal discharge of chronic sinusitis patients.Tohoku J Exp Med. 1997;182(2):115-124.
119. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of
macrolide antibiotics. Eur J Pharmacol. 2001;429(1-3):209-229.
120. Healy DP. Macrolide immunomodulation of chronic respiratory
diseases. Curr Infect Dis Rep. 2007;9(1):7-13.
121. Wallwork B, Coman W, Mackay-Sim A, Greiff L, Cervin A. A
double-blind, randomized, placebo-controlled trial of macrolide in the
treatment of chronic rhinosinusitis. Laryngoscope.2006;116(2):189-193.
122. Videler WJ, Badia L, Harvey RJ, et al. Lack of efficacy of
long-term, low-dose azithromycin in chronic rhinosinusitis: a randomized
controlled trial. Allergy. 2011;66(11):1457-1468.
123. Haruna S, Shimada C, Ozawa M, Fukami S, Moriyama H. A study of poor
responders for long-term, low-dose macrolide administration for chronic
sinusitis. Rhinology. 2009;47(1):66-71.
124. Bezerra TFP, Pezato R, de Barros PM, et al. Prospective evaluation
of clarithromycin in recurrent chronic rhinosinusitis with nasal polyps.Braz J Otorhinolaryngol. 2019.
125. Huang Z, Zhou B. Clarithromycin for the treatment of adult chronic
rhinosinusitis: a systematic review and meta-analysis. Int Forum
Allergy Rhinol. 2019;9(5):545-555.
126. Oakley GM, Harvey RJ, Lund VJ. The Role of Macrolides in Chronic
Rhinosinusitis (CRSsNP and CRSwNP). Curr Allergy Asthma Rep.2017;17(5):30.
127. Seresirikachorn K, Suwanparin N, Srisunthornphanich C,
Chitsuthipakorn W, Kanjanawasee D, Snidvongs K. Factors of success of
low-dose macrolides in chronic sinusitis: Systematic review and
meta-analysis. Laryngoscope. 2019;129(7):1510-1519.
128. Lees KA, Orlandi RR, Oakley G, Alt JA. The Role of Macrolides and
Doxycycline in Chronic Rhinosinusitis. Immunol Allergy Clin North
Am. 2020;40(2):303-315.
129. Henehan M, Montuno M, De Benedetto A. Doxycycline as an
anti-inflammatory agent: updates in dermatology. J Eur Acad
Dermatol Venereol. 2017;31(11):1800-1808.
130. Gueders MM, Bertholet P, Perin F, et al. A novel formulation of
inhaled doxycycline reduces allergen-induced inflammation,
hyperresponsiveness and remodeling by matrix metalloproteinases and
cytokines modulation in a mouse model of asthma. Biochem
Pharmacol. 2008;75(2):514-526.
131. Kuzin, II, Snyder JE, Ugine GD, et al. Tetracyclines inhibit
activated B cell function. Int Immunol. 2001;13(7):921-931.
132. Van Zele T, Gevaert P, Holtappels G, et al. Oral steroids and
doxycycline: two different approaches to treat nasal polyps. J
Allergy Clin Immunol. 2010;125(5):1069-1076 e1064.
133. De Schryver E, Derycke L, Calus L, et al. The effect of systemic
treatments on periostin expression reflects their interference with the
eosinophilic inflammation in chronic rhinosinusitis with nasal polyps.Rhinology. 2017;55(2):152-160.
134. Grammer LC. Doxycycline or oral corticosteroids for nasal polyps.J Allergy Clin Immunol Pract. 2013;1(5):541-542.
135. Cardell LO, Stjarne P, Jonstam K, Bachert C. Endotypes of chronic
rhinosinusitis: Impact on management. J Allergy Clin Immunol.2020;145(3):752-756.
136. Pinto Bezerra Soter AC, Bezerra TF, Pezato R, et al. Prospective
open-label evaluation of long-term low-dose doxycycline for
difficult-to-treat chronic rhinosinusitis with nasal polyps.Rhinology. 2017;55(2):175-180.
137. Sommer JU, Schultz JD, Grossbaier J, Stern-Straeter J, Hormann K,
Sauter A. In vitro effects of doxycycline on inflammatory cytokines and
gelatinases in chronic rhinosinusitis. In Vivo.2012;26(3):369-374.
138. Banuelos J, Lu NZ. A gradient of glucocorticoid sensitivity among
helper T cell cytokines. Cytokine Growth Factor Rev.2016;31:27-35.
139. Raundhal M, Morse C, Khare A, et al. High IFN-gamma and low SLPI
mark severe asthma in mice and humans. J Clin Invest.2015;125(8):3037-3050.
140. Halwani R, Al-Muhsen S, Hamid Q. T helper 17 cells in airway
diseases: from laboratory bench to bedside. Chest.2013;143(2):494-501.
141. Strehl C, Ehlers L, Gaber T, Buttgereit F.
Glucocorticoids-All-Rounders Tackling the Versatile Players of the
Immune System. Front Immunol. 2019;10:1744.
142. Belvisi MG. Regulation of inflammatory cell function by
corticosteroids. Proc Am Thorac Soc. 2004;1(3):207-214.
143. Walford HH, Lund SJ, Baum RE, et al. Increased ILC2s in the
eosinophilic nasal polyp endotype are associated with corticosteroid
responsiveness. Clin Immunol. 2014;155(1):126-135.
144. Doherty TA, Broide DH. Pathways to limit group 2 innate lymphoid
cell activation. J Allergy Clin Immunol. 2017;139(5):1465-1467.
145. Ogasawara N, Poposki JA, Klingler AI, et al. IL-10, TGF-beta, and
glucocorticoid prevent the production of type 2 cytokines in human group
2 innate lymphoid cells. J Allergy Clin Immunol.2018;141(3):1147-1151 e1148.
146. Schleimer RP, Freeland HS, Peters SP, Brown KE, Derse CP. An
assessment of the effects of glucocorticoids on degranulation,
chemotaxis, binding to vascular endothelium and formation of leukotriene
B4 by purified human neutrophils. J Pharmacol Exp Ther.1989;250(2):598-605.
147. Ray A, Kolls JK. Neutrophilic Inflammation in Asthma and
Association with Disease Severity. Trends Immunol.2017;38(12):942-954.
148. Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG.
Different types of intranasal steroids for chronic rhinosinusitis.Cochrane Database Syst Rev. 2016;4:CD011993.
149. Kalish L, Snidvongs K, Sivasubramaniam R, Cope D, Harvey RJ.
Topical steroids for nasal polyps. Cochrane Database Syst Rev.2012;12:CD006549.
150. Head K, Chong LY, Piromchai P, et al. Systemic and topical
antibiotics for chronic rhinosinusitis. Cochrane Database Syst
Rev. 2016;4:CD011994.
151. Zhou B, He G, Liang J, et al. Mometasone furoate nasal spray in the
treatment of nasal polyposis in Chinese patients: a double-blind,
randomized, placebo-controlled trial. Int Forum Allergy Rhinol.2016;6(1):88-94.
152. Hissaria P, Smith W, Wormald PJ, et al. Short course of systemic
corticosteroids in sinonasal polyposis: a double-blind, randomized,
placebo-controlled trial with evaluation of outcome measures. J
Allergy Clin Immunol. 2006;118(1):128-133.
153. Britt RD, Jr., Thompson MA, Sasse S, Pabelick CM, Gerber AN,
Prakash YS. Th1 cytokines TNF-alpha and IFN-gamma promote corticosteroid
resistance in developing human airway smooth muscle. Am J Physiol
Lung Cell Mol Physiol. 2019;316(1):L71-L81.
154. Nabe T. Steroid-Resistant Asthma and Neutrophils. Biol Pharm
Bull. 2020;43(1):31-35.
155. Harvey RJ, Snidvongs K, Kalish LH, Oakley GM, Sacks R.
Corticosteroid nasal irrigations are more effective than simple sprays
in a randomized double-blinded placebo-controlled trial for chronic
rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol.2018;8(4):461-470.
156. Kern RC, Stolovitzky JP, Silvers SL, et al. A phase 3 trial of
mometasone furoate sinus implants for chronic sinusitis with recurrent
nasal polyps. Int Forum Allergy Rhinol. 2018;8(4):471-481.
157. Djupesland PG, Skretting A, Winderen M, Holand T. Breath actuated
device improves delivery to target sites beyond the nasal valve.Laryngoscope. 2006;116(3):466-472.
158. Fokkens W, Reitsma S. New delivery forms of nasal corticosteroids.J Allergy Clin Immunol. 2019;143(1):87-88.
159. Tait S, Kallogjeri D, Suko J, Kukuljan S, Schneider J, Piccirillo
JF. Effect of Budesonide Added to Large-Volume, Low-pressure Saline
Sinus Irrigation for Chronic Rhinosinusitis: A Randomized Clinical
Trial. JAMA Otolaryngol Head Neck Surg. 2018;144(7):605-612.
160. Leopold DA, Elkayam D, Messina JC, Kosik-Gonzalez C, Djupesland PG,
Mahmoud RA. NAVIGATE II: Randomized, double-blind trial of the
exhalation delivery system with fluticasone for nasal polyposis. J
Allergy Clin Immunol. 2019;143(1):126-134 e125.
161. Sekiyama A, Gon Y, Terakado M, et al. Glucocorticoids enhance
airway epithelial barrier integrity. Int Immunopharmacol.2012;12(2):350-357.
162. Steelant B, Farre R, Wawrzyniak P, et al. Impaired barrier function
in patients with house dust mite-induced allergic rhinitis is
accompanied by decreased occludin and zonula occludens-1 expression.J Allergy Clin Immunol. 2016;137(4):1043-1053 e1045.
163. Ordovas-Montanes J, Dwyer DF, Nyquist SK, et al. Allergic
inflammatory memory in human respiratory epithelial progenitor cells.Nature. 2018;560(7720):649-654.
164. Corren J. New Targeted Therapies for Uncontrolled Asthma. J
Allergy Clin Immunol Pract. 2019;7(5):1394-1403.
165. Ghogomu N, Kern R. Chronic rhinosinusitis: the rationale for
current treatments. Expert Rev Clin Immunol. 2017;13(3):259-270.
166. Chin D, Harvey RJ. Nasal polyposis: an inflammatory condition
requiring effective anti-inflammatory treatment. Curr Opin
Otolaryngol Head Neck Surg. 2013;21(1):23-30.
167. Chandra RK, Kern RC, Cutler JL, Welch KC, Russell PT. REMODEL
larger cohort with long-term outcomes and meta-analysis of standalone
balloon dilation studies. Laryngoscope. 2016;126(1):44-50.
168. Leung RM, Kern RC, Conley DB, Tan BK, Chandra RK. Osteomeatal
complex obstruction is not associated with adjacent sinus disease in
chronic rhinosinusitis with polyps. Am J Rhinol Allergy.2011;25(6):401-403.
169. Snidvongs K, Kalish L, Sacks R, Sivasubramaniam R, Cope D, Harvey
RJ. Sinus surgery and delivery method influence the effectiveness of
topical corticosteroids for chronic rhinosinusitis: systematic review
and meta-analysis. Am J Rhinol Allergy. 2013;27(3):221-233.
170. DeConde AS, Smith TL. Outcomes After Frontal Sinus Surgery: An
Evidence-Based Review. Otolaryngol Clin North Am.2016;49(4):1019-1033.
171. Snidvongs K, Pratt E, Chin D, Sacks R, Earls P, Harvey RJ.
Corticosteroid nasal irrigations after endoscopic sinus surgery in the
management of chronic rhinosinusitis. Int Forum Allergy Rhinol.2012;2(5):415-421.
172. Bassiouni A, Ou J, Rajiv S, Cantero D, Vreugde S, Wormald PJ.
Subepithelial inflammatory load and basement membrane thickening in
refractory chronic rhinosinusitis with nasal polyposis: a
histopathological study. Int Forum Allergy Rhinol.2016;6(3):248-255.
173. Jankowski R, Bodino C. Evolution of symptoms associated to nasal
polyposis following oral steroid treatment and nasalization of the
ethmoid–radical ethmoidectomy is functional surgery for NPS.Rhinology. 2003;41(4):211-219.
174. Barham HP, Ramakrishnan VR, Knisely A, et al. Frontal sinus surgery
and sinus distribution of nasal irrigation. Int Forum Allergy
Rhinol. 2016;6(3):238-242.
175. Alsharif S, Jonstam K, van Zele T, Gevaert P, Holtappels G, Bachert
C. Endoscopic Sinus Surgery for Type-2 CRS wNP: An Endotype-Based
Retrospective Study. Laryngoscope. 2019;129(6):1286-1292.
176. Morrissey DK, Bassiouni A, Psaltis AJ, Naidoo Y, Wormald PJ.
Outcomes of modified endoscopic Lothrop in aspirin-exacerbated
respiratory disease with nasal polyposis. Int Forum Allergy
Rhinol. 2016;6(8):820-825.
177. Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in
initial immunoprofiles between recurrent and nonrecurrent chronic
rhinosinusitis with nasal polyps. Am J Rhinol Allergy.2014;28(3):192-198.
178. Lou H, Fang J, Li P, et al. Frequency, suppressive capacity,
recruitment and induction mechanisms of regulatory T cells in sinonasal
squamous cell carcinoma and nasal inverted papilloma. PLoS One.2015;10(5):e0126463.
179. Tokunaga T, Sakashita M, Haruna T, et al. Novel scoring system and
algorithm for classifying chronic rhinosinusitis: the JESREC Study.Allergy. 2015;70(8):995-1003.
180. Khairuddin NK, Salina H, Gendeh BS, Wan Hamizan AK, Lund VJ.
Quality of life and recurrence of disease in patients with eosinophilic
and non-eosinophilic 1 chronic rhinosinusitis with nasal polyposis.Med J Malaysia. 2018;73(1):1-6.
181. Rosati D, Rosato C, Pagliuca G, et al. Predictive markers of
long-term recurrence in chronic rhinosinusitis with nasal polyps.Am J Otolaryngol. 2020;41(1):102286.
182. Pan L, Liao B, Guo CL, et al. Inflammatory features and predictors
for postsurgical outcomes in patients with nasal polyps stratified by
local and systemic eosinophilia. Int Forum Allergy Rhinol. 2020.
183. Ryu G, Kim DK, Dhong HJ, et al. Immunological Characteristics in
Refractory Chronic Rhinosinusitis with Nasal Polyps Undergoing Revision
Surgeries. Allergy Asthma Immunol Res. 2019;11(5):664-676.
184. Bachert C, Mannent L, Naclerio RM, et al. Effect of Subcutaneous
Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and
Nasal Polyposis: A Randomized Clinical Trial. JAMA.2016;315(5):469-479.
185. Chang TW, Davis FM, Sun NC, Sun CR, MacGlashan DW, Jr., Hamilton
RG. Monoclonal antibodies specific for human IgE-producing B cells: a
potential therapeutic for IgE-mediated allergic diseases.Biotechnology (N Y). 1990;8(2):122-126.
186. Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting
on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP)
and biologics: Definitions and management. J Allergy Clin
Immunol. 2021;147(1):29-36.
187. Hopkins C, Slack R, Lund V, Brown P, Copley L, Browne J. Long-term
outcomes from the English national comparative audit of surgery for
nasal polyposis and chronic rhinosinusitis. Laryngoscope.2009;119(12):2459-2465.
188. Smith TL, Schlosser RJ, Mace JC, et al. Long-term outcomes of
endoscopic sinus surgery in the management of adult chronic
rhinosinusitis. Int Forum Allergy Rhinol. 2019;9(8):831-841.
189. Smith KA, Orlandi RR, Oakley G, Meeks H, Curtin K, Alt JA.
Long-term revision rates for endoscopic sinus surgery. Int Forum
Allergy Rhinol. 2019;9(4):402-408.